James B. Ford
No Rating Available
(Learn About Our Rating System)

James B. Ford, DO

Languages spoken: English, Portuguese, Spanish

Clinical Locations

Primary Children's Hospital

Pediatric Hematology/Oncology
Salt Lake City

  • Dr. Ford is currently an associate professor at the University of Utah School of Medicine in the division of Pediatric Hematology/Oncology. He is a member of the Leukemia and Lymphoma Team at the University of Utah and Primary Children’s Hospital. He received his medical degree from Des Moines University College of Osteopathic Medicine.

    Dr. Ford completed his residency at Akron Children’s Hospital specializing in Pediatrics. He pursued his Hematology, Oncology and Bone Marrow Transplantation Fellowship at the University of Colorado School of Medicine, Children’s Hospital Colorado.

    Dr. Ford is board-certified in Pediatrics and Pediatric Hematology and Oncology. He has authored several articles in peer-reviewed journals and has been the principal investigator in several grants.

    Dr. Ford’s clinical interests include the treatment of pediatric Leukemia and Lymphoma. He has an emphasis in post-transplant lymphoproliferative disorder and Non-Hodgkin Lymphomas.

    His primary research focuses on Non-Hodgkin Lymphoma. He is involved in clinical trials for relapsed T-cell lymphoblastic lymphoma and relapsed mature B cell lymphoma. He is also interested in discovering risk factors leading to relapse in T-cell lymphoblastic lymphoma.

    Specialties

    Board Certification

    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

  • Dr. Ford is currently an associate professor at the University of Utah School of Medicine in the division of Pediatric Hematology/Oncology. He is a member of the Leukemia and Lymphoma Team at the University of Utah and Primary Children’s Hospital. He received his medical degree from Des Moines University College of Osteopathic Medicine.

    Dr. Ford completed his residency at Akron Children’s Hospital specializing in Pediatrics. He pursued his Hematology, Oncology and Bone Marrow Transplantation Fellowship at the University of Colorado School of Medicine, Children’s Hospital Colorado.

    Dr. Ford is board-certified in Pediatrics and Pediatric Hematology and Oncology. He has authored several articles in peer-reviewed journals and has been the principal investigator in several grants.

    Dr. Ford’s clinical interests include the treatment of pediatric Leukemia and Lymphoma. He has an emphasis in post-transplant lymphoproliferative disorder and Non-Hodgkin Lymphomas.

    His primary research focuses on Non-Hodgkin Lymphoma. He is involved in clinical trials for relapsed T-cell lymphoblastic lymphoma and relapsed mature B cell lymphoma. He is also interested in discovering risk factors leading to relapse in T-cell lymphoblastic lymphoma.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Primary
    Academic Divisions Hematology/Oncology
    Board Certification
    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

    Education history

    Fellowship Hematology, Oncology and Bone Marrow Transplantation - University of Colorado School of Medicine, Children’s Hospital Colorado Fellow
    Pediatrics - Northeast Ohio Medical University, Akron Children's Hospital Resident
    Professional Medical Osteopathic Medicine - Des Moines University College of Osteopathic Medicine D.O.
    Double Major: Biology and Behavioral Science & Health - University of Utah B.S.

    Selected Publications

    Journal Article

    1. Afify ZAM, Taj MM, Orjuela-Grimm M, Srivatsa K, Miller TP, Edington HJ, Dalal M, Robles J, Ford JB, Ehrhardt MJ, Ureda TJ, Rubinstein JD, McCormack S, Rivers JM, Chisholm KM, Kavanaugh MK, Bukowinski AJ, Friehling ED, Ford MC, Reddy SN, Marks LJ, Smith CM, Mason CC (2022). Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders. Cancer, 129(5), 780-789. (Read full article)
    2. Cave C, Ramirez R, High R, Ford J, Raulji C, Beck J (2023). Vincristine Side Effects With Concomitant Fluconazole Use During Induction Chemotherapy in Pediatric Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. (Read full article)
    3. Haney SL, Feng D, Chhonker YS, Varney ML, Williams JT, Smith LM, Ford JB, Murry DJ, Holstein SA (2022). Evaluation of geranylgeranyl diphosphate synthase inhibition as a novel strategy for the treatment of osteosarcoma and Ewing sarcoma. Drug Dev Res, 84(1), 62-74. (Read full article)
    4. Afify Z, Orjuela-Grimm M, Smith CM, Dalal M, Ford JB, Pillai P, Robles JM, Reddy S, McCormack S, Ehrhardt MJ, Ureda T, Alperstein W, Edington H, Miller TP, Rubinstein JD, Kavanaugh M, Bukowinski AJ, Friehling E, Rivers JM, Chisholm KM, Marks LJ, Mason CC (2022). Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative. Br J Haematol, 200(3), 297-305. (Read full article)
    5. Cochran T, Patel S, Kruse T, Lyden E, Comer S, Ford J (2022). Sensitivity and Specificity of Whole-body MRI for the Detection of Pediatric Malignancy. J Pediatr Hematol Oncol, 45(1), e26-e30. (Read full article)
    6. Barth M, Xavier AC, Armenian S, Audino AN, Blazin L, Bloom D, Chung J, Davies K, Ding H, Ford JB, Galardy PJ, Hanna R, Hayashi R, Lee-Miller C, Machnitz AJ, Maloney KW, Marks L, Martin PL, McCall D, Pacheco M, Reilly AF, Roshal M, Song S, Weinstein J, Zarnegar-Lumley S, McMillian N, Schonfeld R, Sundar H (2022). Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 20(11), 1267-1275. (Read full article)
    7. Slatnick LR, Thornhill D, Deakyne Davies SJ, Ford JB, Scott HF, Manco-Johnson MJ, Warren BB (2020). Disseminated Intravascular Coagulation Is an Independent Predictor of Adverse Outcomes in Children in the Emergency Department with Suspected Sepsis. J Pediatr, 225, 198-206.e2. (Read full article)
    8. Davies K, Barth M, Armenian S, Audino AN, Barnette P, Cuglievan B, Ding H, Ford JB, Galardy PJ, Gardner R, Hanna R, Hayashi R, Kovach AE, Machnitz AJ, Maloney KW, Marks L, Page K, Reilly AF, Weinstein JL, Xavier AC, McMillian NR, Freedman-Cass DA (2020). Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(8), 1105-1123. (Read full article)
    9. Allison J, Drury L, Ford JB (2019). Two Novel TMPRSS6 Variants in a Compound Heterozygous Child With Iron Refractory Iron Deficiency Anemia. J Pediatr Hematol Oncol, 42(4), e238-e239. (Read full article)
    10. Wolf A, Rohr JM, Amador C, Starr LJ, Hoyer JD, Ford JB (2019). Hb Gibbon [β124(H2)Pro→Thr (HBB: c.373C>A, p.P125T)], an Asymptomatic Novel Hemoglobin Variant Detected by Newborn Screening. Hemoglobin, 43(3), 207-209. (Read full article)
    11. Hagelstrom RT, Ford J, Reiser GM, Nelson M, Pickering DL, Althof PA, Sanger WG, Coccia PF (2015). Breast Cancer and Non-Hodgkin Lymphoma in a Young Male with Cowden Syndrome. Pediatr Blood Cancer, 63(3), 544-6. (Read full article)
    12. Ford JB, Baturin D, Burleson TM, Van Linden AA, Kim YM, Porter CC (2015). AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Oncotarget, 6(29), 28001-10. (Read full article)
    13. Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC (2013). Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther, 12(12), 2675-84. (Read full article)